nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—ABCB1—adrenal gland cancer	0.731	1	CbGaD
Sirolimus—EIF4E—gonad—adrenal gland cancer	0.00505	0.142	CbGeAlD
Sirolimus—FGF2—pituitary gland—adrenal gland cancer	0.00301	0.0845	CbGeAlD
Sirolimus—FGF2—adrenal gland—adrenal gland cancer	0.00269	0.0754	CbGeAlD
Sirolimus—CYP3A4—urine—adrenal gland cancer	0.00262	0.0736	CbGeAlD
Sirolimus—FKBP1A—adrenal cortex—adrenal gland cancer	0.00212	0.0596	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—adrenal gland cancer	0.0021	0.532	CrCbGaD
Sirolimus—MTOR—gonad—adrenal gland cancer	0.00196	0.0549	CbGeAlD
Sirolimus—MTOR—pituitary gland—adrenal gland cancer	0.00191	0.0536	CbGeAlD
Sirolimus—Tacrolimus—ABCB1—adrenal gland cancer	0.00185	0.468	CrCbGaD
Sirolimus—SLC47A1—adrenal cortex—adrenal gland cancer	0.00182	0.0513	CbGeAlD
Sirolimus—FKBP1A—gonad—adrenal gland cancer	0.00176	0.0494	CbGeAlD
Sirolimus—FKBP1A—cardiac atrium—adrenal gland cancer	0.00176	0.0493	CbGeAlD
Sirolimus—FKBP1A—pituitary gland—adrenal gland cancer	0.00172	0.0482	CbGeAlD
Sirolimus—MTOR—adrenal gland—adrenal gland cancer	0.0017	0.0479	CbGeAlD
Sirolimus—FKBP1A—adrenal gland—adrenal gland cancer	0.00153	0.0431	CbGeAlD
Sirolimus—SLC47A1—gonad—adrenal gland cancer	0.00151	0.0425	CbGeAlD
Sirolimus—SLC47A1—pituitary gland—adrenal gland cancer	0.00147	0.0414	CbGeAlD
Sirolimus—SLC47A1—adrenal gland—adrenal gland cancer	0.00132	0.037	CbGeAlD
Sirolimus—ABCB1—adrenal cortex—adrenal gland cancer	0.000491	0.0138	CbGeAlD
Sirolimus—ABCB1—gonad—adrenal gland cancer	0.000407	0.0114	CbGeAlD
Sirolimus—ABCB1—pituitary gland—adrenal gland cancer	0.000397	0.0111	CbGeAlD
Sirolimus—ABCB1—adrenal gland—adrenal gland cancer	0.000355	0.00996	CbGeAlD
Sirolimus—FGF2—Signaling by NGF—BRAF—adrenal gland cancer	0.000213	0.000931	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TSHR—adrenal gland cancer	0.000213	0.00093	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	0.000213	0.000929	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MEN1—adrenal gland cancer	0.00021	0.000916	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—EGFR—adrenal gland cancer	0.000208	0.00091	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—EGFR—adrenal gland cancer	0.000207	0.000902	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000206	0.0009	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—adrenal gland cancer	0.000206	0.000898	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—EGFR—adrenal gland cancer	0.000206	0.000898	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—EGFR—adrenal gland cancer	0.000206	0.000898	CbGpPWpGaD
Sirolimus—MTOR—Disease—ZNRF3—adrenal gland cancer	0.000205	0.000897	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—EGFR—adrenal gland cancer	0.000202	0.000884	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—EGFR—adrenal gland cancer	0.000202	0.000882	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—adrenal gland cancer	0.000202	0.000882	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CDC42—adrenal gland cancer	0.0002	0.000876	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MEN1—adrenal gland cancer	0.0002	0.000874	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.0002	0.000872	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—adrenal gland cancer	0.000198	0.000866	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—CTNNB1—adrenal gland cancer	0.000198	0.000865	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000194	0.000846	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—POMC—adrenal gland cancer	0.000193	0.000845	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—EGFR—adrenal gland cancer	0.000193	0.000844	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—EGFR—adrenal gland cancer	0.000192	0.00084	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—EGFR—adrenal gland cancer	0.000191	0.000836	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CDC42—adrenal gland cancer	0.000191	0.000836	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—CTNNB1—adrenal gland cancer	0.000191	0.000832	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—EGFR—adrenal gland cancer	0.00019	0.000832	CbGpPWpGaD
Sirolimus—CYP3A7—Biological oxidations—POMC—adrenal gland cancer	0.00019	0.000829	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—adrenal gland cancer	0.000188	0.00082	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	0.000187	0.000816	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SDHB—adrenal gland cancer	0.000185	0.000808	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CDC42—adrenal gland cancer	0.000184	0.000803	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—EGFR—adrenal gland cancer	0.000179	0.000782	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—EGFR—adrenal gland cancer	0.000179	0.000782	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—EGFR—adrenal gland cancer	0.000179	0.000782	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—EGFR—adrenal gland cancer	0.000177	0.000775	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—EGFR—adrenal gland cancer	0.000176	0.000769	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNRH1—adrenal gland cancer	0.000175	0.000765	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—EGFR—adrenal gland cancer	0.000175	0.000765	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—BAD—adrenal gland cancer	0.000174	0.000759	CbGpPWpGaD
Sirolimus—FGF2—Disease—SPRY2—adrenal gland cancer	0.000173	0.000758	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SDHB—adrenal gland cancer	0.00017	0.000742	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—adrenal gland cancer	0.000169	0.00074	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	0.000169	0.000736	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PRKACA—adrenal gland cancer	0.000167	0.000731	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—EGFR—adrenal gland cancer	0.000166	0.000724	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—RB1—adrenal gland cancer	0.000166	0.000724	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNRHR—adrenal gland cancer	0.000164	0.000719	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PRKACA—adrenal gland cancer	0.000161	0.000702	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SPRY2—adrenal gland cancer	0.00016	0.0007	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PRKACA—adrenal gland cancer	0.00016	0.000699	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—EGFR—adrenal gland cancer	0.000159	0.000697	CbGpPWpGaD
Sirolimus—FGF2—Disease—MEN1—adrenal gland cancer	0.000159	0.000694	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—EGFR—adrenal gland cancer	0.000159	0.000693	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—BRAF—adrenal gland cancer	0.000158	0.000691	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TSHR—adrenal gland cancer	0.000156	0.000682	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000153	0.000668	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PRKACA—adrenal gland cancer	0.000153	0.000667	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—adrenal gland cancer	0.000153	0.000666	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—adrenal gland cancer	0.000151	0.000659	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—EGFR—adrenal gland cancer	0.00015	0.000656	CbGpPWpGaD
Sirolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.000148	0.000647	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MEN1—adrenal gland cancer	0.000147	0.000641	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—CDKN2A—adrenal gland cancer	0.000146	0.000636	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000146	0.000636	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000144	0.000628	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—EGFR—adrenal gland cancer	0.000143	0.000626	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—EGFR—adrenal gland cancer	0.000143	0.000623	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—adrenal gland cancer	0.000143	0.000623	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—EGFR—adrenal gland cancer	0.000142	0.00062	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CDC42—adrenal gland cancer	0.000142	0.00062	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	0.000141	0.000618	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—EGFR—adrenal gland cancer	0.000141	0.000617	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—BAD—adrenal gland cancer	0.00014	0.000611	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—adrenal gland cancer	0.000139	0.000608	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	0.000138	0.000605	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—CTNNB1—adrenal gland cancer	0.000138	0.000603	CbGpPWpGaD
Sirolimus—CYP3A5—Biological oxidations—POMC—adrenal gland cancer	0.000137	0.0006	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CDC42—adrenal gland cancer	0.000136	0.000596	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CDC42—adrenal gland cancer	0.000136	0.000593	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—BAD—adrenal gland cancer	0.000134	0.000583	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—adrenal gland cancer	0.000133	0.000581	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—adrenal gland cancer	0.000133	0.000581	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—adrenal gland cancer	0.000133	0.000581	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNRH1—adrenal gland cancer	0.000133	0.00058	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—adrenal gland cancer	0.000132	0.000575	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PRKACA—adrenal gland cancer	0.000131	0.000574	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—adrenal gland cancer	0.000131	0.00057	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—adrenal gland cancer	0.00013	0.000568	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CDC42—adrenal gland cancer	0.00013	0.000566	CbGpPWpGaD
Sirolimus—MTOR—Disease—SPRY2—adrenal gland cancer	0.000129	0.000562	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—BAD—adrenal gland cancer	0.000128	0.00056	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—adrenal gland cancer	0.000127	0.000554	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IGF2—adrenal gland cancer	0.000125	0.000546	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—GNAS—adrenal gland cancer	0.000124	0.000541	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—adrenal gland cancer	0.000123	0.000537	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SDHB—adrenal gland cancer	0.000123	0.000536	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—adrenal gland cancer	0.000122	0.000533	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SPRY2—adrenal gland cancer	0.000121	0.000531	CbGpPWpGaD
Sirolimus—FGF2—Disease—PRKACA—adrenal gland cancer	0.000121	0.00053	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IGF1R—adrenal gland cancer	0.000121	0.000528	CbGpPWpGaD
Sirolimus—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.00012	0.000525	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—RRM1—adrenal gland cancer	0.000119	0.000521	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SDHD—adrenal gland cancer	0.000119	0.000521	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TSHR—adrenal gland cancer	0.000118	0.000517	CbGpPWpGaD
Sirolimus—MTOR—Disease—MEN1—adrenal gland cancer	0.000118	0.000515	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—adrenal gland cancer	0.000118	0.000514	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	0.000112	0.00049	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PRKACA—adrenal gland cancer	0.000112	0.00049	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CDC42—adrenal gland cancer	0.000111	0.000487	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MEN1—adrenal gland cancer	0.000111	0.000486	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	0.00011	0.000481	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SDHD—adrenal gland cancer	0.000109	0.000478	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—RRM1—adrenal gland cancer	0.000109	0.000478	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TERT—adrenal gland cancer	0.000109	0.000476	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TERT—adrenal gland cancer	0.000104	0.000454	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	0.000103	0.000451	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDC42—adrenal gland cancer	0.000103	0.000449	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CTNNB1—adrenal gland cancer	9.95e-05	0.000435	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—BAD—adrenal gland cancer	9.91e-05	0.000433	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNRH1—adrenal gland cancer	9.85e-05	0.00043	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PRKACA—adrenal gland cancer	9.75e-05	0.000426	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—BAD—adrenal gland cancer	9.51e-05	0.000416	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDC42—adrenal gland cancer	9.51e-05	0.000415	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—BAD—adrenal gland cancer	9.47e-05	0.000414	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SDHB—adrenal gland cancer	9.26e-05	0.000404	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CTNNB1—adrenal gland cancer	9.2e-05	0.000402	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF2—adrenal gland cancer	9.16e-05	0.0004	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—GNAS—adrenal gland cancer	9.08e-05	0.000397	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—adrenal gland cancer	9.05e-05	0.000396	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—BAD—adrenal gland cancer	9.04e-05	0.000395	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SPRY2—adrenal gland cancer	9.01e-05	0.000394	CbGpPWpGaD
Sirolimus—MTOR—Disease—PRKACA—adrenal gland cancer	9e-05	0.000393	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MED12—adrenal gland cancer	8.89e-05	0.000388	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IGF1R—adrenal gland cancer	8.86e-05	0.000387	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CTNNB1—adrenal gland cancer	8.78e-05	0.000384	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TSHR—adrenal gland cancer	8.78e-05	0.000384	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—BRAF—adrenal gland cancer	8.62e-05	0.000377	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PRKACA—adrenal gland cancer	8.49e-05	0.000371	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—POMC—adrenal gland cancer	8.34e-05	0.000364	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDC42—adrenal gland cancer	8.27e-05	0.000361	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MEN1—adrenal gland cancer	8.26e-05	0.000361	CbGpPWpGaD
Sirolimus—FGF2—Disease—TERT—adrenal gland cancer	8.25e-05	0.000361	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—BRAF—adrenal gland cancer	8.23e-05	0.00036	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MED12—adrenal gland cancer	8.15e-05	0.000356	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—adrenal gland cancer	8.1e-05	0.000354	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	7.94e-05	0.000347	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—RRM1—adrenal gland cancer	7.91e-05	0.000345	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SDHD—adrenal gland cancer	7.91e-05	0.000345	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—adrenal gland cancer	7.88e-05	0.000344	CbGpPWpGaD
Sirolimus—FGF2—Immune System—BAD—adrenal gland cancer	7.78e-05	0.00034	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDC42—adrenal gland cancer	7.63e-05	0.000334	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TERT—adrenal gland cancer	7.63e-05	0.000333	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	7.59e-05	0.000332	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—adrenal gland cancer	7.29e-05	0.000319	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDC42—adrenal gland cancer	7.2e-05	0.000315	CbGpPWpGaD
Sirolimus—FGF2—Disease—BAD—adrenal gland cancer	7.18e-05	0.000314	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTGS2—adrenal gland cancer	6.97e-05	0.000304	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—adrenal gland cancer	6.96e-05	0.000304	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF2—adrenal gland cancer	6.94e-05	0.000303	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	6.93e-05	0.000303	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GNAS—adrenal gland cancer	6.88e-05	0.000301	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	6.8e-05	0.000297	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IGF1R—adrenal gland cancer	6.71e-05	0.000293	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—adrenal gland cancer	6.68e-05	0.000292	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—BAD—adrenal gland cancer	6.63e-05	0.00029	CbGpPWpGaD
Sirolimus—FGF2—Disease—BRAF—adrenal gland cancer	6.54e-05	0.000286	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CTNNB1—adrenal gland cancer	6.52e-05	0.000285	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PRKACA—adrenal gland cancer	6.48e-05	0.000283	CbGpPWpGaD
Sirolimus—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	6.38e-05	0.000279	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	6.34e-05	0.000277	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PRKACA—adrenal gland cancer	6.3e-05	0.000275	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CTNNB1—adrenal gland cancer	6.23e-05	0.000272	CbGpPWpGaD
Sirolimus—MTOR—Disease—TERT—adrenal gland cancer	6.12e-05	0.000268	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—POMC—adrenal gland cancer	6.12e-05	0.000267	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—BRAF—adrenal gland cancer	6.04e-05	0.000264	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—RRM1—adrenal gland cancer	5.97e-05	0.000261	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SDHD—adrenal gland cancer	5.97e-05	0.000261	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CTNNB1—adrenal gland cancer	5.95e-05	0.00026	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PRKACA—adrenal gland cancer	5.95e-05	0.00026	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MED12—adrenal gland cancer	5.89e-05	0.000258	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TERT—adrenal gland cancer	5.78e-05	0.000252	CbGpPWpGaD
Sirolimus—MTOR—Immune System—BAD—adrenal gland cancer	5.77e-05	0.000252	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SDHB—adrenal gland cancer	5.7e-05	0.000249	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	5.62e-05	0.000245	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	5.38e-05	0.000235	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDC42—adrenal gland cancer	5.35e-05	0.000234	CbGpPWpGaD
Sirolimus—MTOR—Disease—BAD—adrenal gland cancer	5.33e-05	0.000233	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—adrenal gland cancer	5.28e-05	0.000231	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GNAS—adrenal gland cancer	5.25e-05	0.00023	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—adrenal gland cancer	5.16e-05	0.000226	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—adrenal gland cancer	5.16e-05	0.000225	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF2—adrenal gland cancer	5.15e-05	0.000225	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—adrenal gland cancer	5.12e-05	0.000224	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GNAS—adrenal gland cancer	5.11e-05	0.000223	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BAD—adrenal gland cancer	5.03e-05	0.00022	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IGF1R—adrenal gland cancer	4.98e-05	0.000218	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—adrenal gland cancer	4.96e-05	0.000217	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—adrenal gland cancer	4.94e-05	0.000216	CbGpPWpGaD
Sirolimus—MTOR—Disease—BRAF—adrenal gland cancer	4.85e-05	0.000212	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GNAS—adrenal gland cancer	4.82e-05	0.000211	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—adrenal gland cancer	4.73e-05	0.000207	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—adrenal gland cancer	4.72e-05	0.000206	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—adrenal gland cancer	4.71e-05	0.000206	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—POMC—adrenal gland cancer	4.63e-05	0.000202	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BRAF—adrenal gland cancer	4.58e-05	0.0002	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	4.52e-05	0.000197	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MED12—adrenal gland cancer	4.45e-05	0.000194	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—adrenal gland cancer	4.36e-05	0.000191	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PRKACA—adrenal gland cancer	4.3e-05	0.000188	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—adrenal gland cancer	4.29e-05	0.000187	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—adrenal gland cancer	4.05e-05	0.000177	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—adrenal gland cancer	3.96e-05	0.000173	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—adrenal gland cancer	3.92e-05	0.000171	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—adrenal gland cancer	3.8e-05	0.000166	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—adrenal gland cancer	3.74e-05	0.000163	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BAD—adrenal gland cancer	3.73e-05	0.000163	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RRM1—adrenal gland cancer	3.68e-05	0.000161	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SDHD—adrenal gland cancer	3.68e-05	0.000161	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—POMC—adrenal gland cancer	3.54e-05	0.000155	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—adrenal gland cancer	3.51e-05	0.000153	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GNAS—adrenal gland cancer	3.49e-05	0.000152	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—adrenal gland cancer	3.46e-05	0.000151	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—POMC—adrenal gland cancer	3.44e-05	0.00015	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—adrenal gland cancer	3.42e-05	0.000149	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—adrenal gland cancer	3.4e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—adrenal gland cancer	3.31e-05	0.000145	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—POMC—adrenal gland cancer	3.25e-05	0.000142	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PRKACA—adrenal gland cancer	3.24e-05	0.000142	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—adrenal gland cancer	3.01e-05	0.000131	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—adrenal gland cancer	2.9e-05	0.000127	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—adrenal gland cancer	2.82e-05	0.000123	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—adrenal gland cancer	2.78e-05	0.000121	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MED12—adrenal gland cancer	2.74e-05	0.00012	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GNAS—adrenal gland cancer	2.63e-05	0.000115	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—adrenal gland cancer	2.62e-05	0.000114	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—adrenal gland cancer	2.59e-05	0.000113	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—adrenal gland cancer	2.45e-05	0.000107	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—POMC—adrenal gland cancer	2.35e-05	0.000103	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—adrenal gland cancer	2.2e-05	9.61e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	2e-05	8.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—adrenal gland cancer	1.94e-05	8.5e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—adrenal gland cancer	1.87e-05	8.18e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—POMC—adrenal gland cancer	1.77e-05	7.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—adrenal gland cancer	1.63e-05	7.13e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNAS—adrenal gland cancer	1.62e-05	7.08e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	1.59e-05	6.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—adrenal gland cancer	1.41e-05	6.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—POMC—adrenal gland cancer	1.09e-05	4.77e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	8.7e-06	3.8e-05	CbGpPWpGaD
